The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study
Open accessAbstract
MedDRA Medical
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Randomized clinical trial data from an open-label 5-year trial of insulin glargine versus NPH insulin did not find evidence of excess cancer risk (all sites combined) in the insulin glargine arm (118), although among the ∼1,000 subjects randomized, there was a very small number of cancer end points (57 cancer cases in the glargine arm and 62 cases in the NPH arm).”
From Diabetes and Cancer (2010) · cites this paper as [118]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124
Hemkens, L. G., Grouven, U., Bender, R., Günster, C., Gutschmidt, S., Selke, G. W., & Sawicki, P. T. (2009) · Diabetologia · doi:10.1007/s00125-009-1418-4 · Cited by 607
Jonasson, J. M., Ljung, R., Talbäck, M., Haglund, B., Gudbjörnsdòttir, S., & Steineck, G. (2009) · Diabetologia · doi:10.1007/s00125-009-1444-2 · Cited by 412
SDRN Epidemiology Group, & Colhoun, H. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1453-1 · Cited by 387
Rosenstock, J., Fonseca, V. A., McGill, J. B., Riddle, M. C., Hallé, J., HRAMIAK, I. M., Johnston, P., & Davis, J. L. (2009) · Diabetologia · doi:10.1007/s00125-009-1415-7 · Cited by 87
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–138 of 138
New insulins and the risk of cancer
Danne, T., & Bolinder, J. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02275.x · Cited by 3
Insulin, other hypoglycemic drugs, and glucagon
Page, R. C. (2010) · Side effects of drugs annual · doi:10.1016/s0378-6080(10)32042-3 · Cited by 2
Influence of metformin therapy on breast cancer incidence and prognosis
Popovic, Ð., POPOVIC, L. S., Stokić, E., Tomić-Naglić, D., Mitrović, M., & Kovačev-Zavišić, B. (2012) · Archive of oncology · doi:10.2298/aoo1204062p · Cited by 2
Faillie, J., & Bringer, J. (2014) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(14)70833-8 · Cited by 2
Carcinogenicity of Biopharmaceuticals
Dempster, M., Siezen, K., ter Braak, B., van den Brink, W., Emerenciana, A., Bellanti, F., Duijnhoven, R. G., Kwa, M., & van der Laan, J. W. (2015) · Springer eBooks · doi:10.1007/978-3-319-22084-0_8 · Cited by 2
Critical appraisal of the recent data published on the link between insulin and cancer
Ghosal, S., Stephens, J., Deventer, A. V., Mital, V., Jayasinghe, P., Khan, M. A., Setch, L., & Pauly, B. (2011) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2012.03.004 · Cited by 2
Mistakes, misunderstandings and controversies in diabetes: A review and personal account
Mogensen, C. E. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00012.x · Cited by 1
Stellenwert von Langzeit-Insulin-Analoga in der Therapie des Diabetes mellitus Typ 2
Ludvik, B. H., Brath, H., Wascher, T. C., & Toplak, H. (2009) · Wiener klinische Wochenschrift · doi:10.1007/s00508-009-1209-4 · Cited by 1
Qi, J., He, P., Yao, H., Sun, W., Lu, P., Zhang, Z., Cui, B., & Ning, G. (2023) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-023-01230-3 · Cited by 1
Insulin Analogues: Reviewing the Pros and Cons in Managing Diabetes Mellitus
Russell, A. W., Prins, J. B., & Martin, J. H. (2011) · Journal of Pharmacogenomics & Pharmacoproteomics · doi:10.4172/2153-0645.1000106 · Cited by 1
Are we helping or harming our insulin-treated diabetic patients during ambulatory treatment?
Szczęśniak, G., Dziemidok, P., & Paprzycki, P. (2013) · PubMed · Cited by 1
Bordeleau, L. J., & Gerstein, H. C. (2014) · Diabetes Care · doi:10.2337/dc14-1220 · Cited by 1
Safety of insulin analogues in diabetes: the lessons of summer 2009
Bolli, G. B., Ampudia‐Blasco, F. J., & Rosenstock, J. (2009) · Avances en Diabetología · Cited by 1
Self-citationHome, P., & Lagarenne, P. (2010) · Diabetologia · doi:10.1007/s00125-009-1656-5 · Cited by 1
The role of insulin and IGF2 signalling on metabolic pathways in prostate cancer progression
Lubik, A. A. (2011) · Faculty of Science and Technology; Institute of Health and Biomedical Innovation
Diabetes‐Associated Comorbidities
(2011) · Wiley eBooks · doi:10.1002/9781119950424.ch9
Sicherheit von Insulin Glargin
Scherbaum, W. A. (2009) · Der Diabetologe · doi:10.1007/s11428-009-0474-1
Risk of oncological diseases in patients with diabetes mellitus
Galstyan, G. R. (2009) · Diabetes Mellitus · doi:10.14341/2072-0351-5715
Führt eine Insulintherapie mit Glargin zu einer erhöhten Rate von Krebsneuerkrankungen?
Hermanns, N. (2009) · Der Diabetologe · doi:10.1007/s11428-009-0473-2
Diabetes, Insulin Resistance, and Cancer: An Update
de Miguel-Yanes, J. M. (2010) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-010-0136-2
Insulina glargina y riesgo de cáncer
Rigla, M. (2009) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(09)72707-x
Insulin Glargine and Incidence of Cancer--An Ongoing Debate
Hermanns, N., & Kulzer, B. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400235
Seguridad de los análogos de insulina: qué evaluar, cómo hacerlo y cómo interpretar los resultados
Hernández‐Mijares, A., Izquierdo, E. S., Malpartida, K. G., & Verge, D. (2010) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2010.05.001
Staffa, J. (2013) · Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.16276
Rosenstock, J., Fonseca, V. A., McGill, J. B., Riddle, M. C., Hallé, J., HRAMIAK, I. M., Johnston, P., & Davis, J. L. (2009) · Diabetologia · doi:10.1007/s00125-009-1492-7
Self-citationNoto, H., Goto, A., Tsujimoto, T., & Noda, M. (2013) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.102.869
Editorial Insulina glargina y riesgo de cáncer
Rigla, M. (2016)
Metformin and Prostate Cancer among Diabetic Men
Margel, D. (2014) · TSpace (University of Toronto)
Bazarbekovna, B. R., Bektayeva, I. S., Konyrbayeva, A. B., Omarova, M. M., Abseitova, D. K., Kazbekova, A., Suslova, I. A., Moldasheva, A. T., Balazhanova, N. E., & Abdazimova, S. M. (2018) · Journal Medicine · doi:10.31082/1728-452x-2018-198-12-41-54
Type 2 diabetes mellitus and gastrointestinal cancer
de Jong (2019) · Research Publications (Maastricht University) · doi:10.26481/dis.20190605rj
Malignancy Concerns With Antidiabetic Therapies: Examining the Evidence
Lebovitz, H. E. (2010) · Endocrine Practice · doi:10.1016/s1530-891x(20)42872-1
Karadeniz (2013) · Journal of Endocrinology and Diabetes Mellitus · doi:10.12970/2310-9971.2013.01.02.2
Krans, H. (2010) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.1427961.904061
Bordeleau, L. J., & Gerstein, H. C. (2014) · Diabetes Care · doi:10.2337/dc14-1567
(2010) · Diabetes Care · doi:10.2337/dc11-s098
New Insulins, Biosimilars, and Insulin Therapy
Biester, T., & Heinemann, L. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.8804.tor
Danne, T., Freckmann, G., Kautzky‐Willer, A., Lang, U. E., Lehmann, R., Pfohl, M., Schloot, N. C., & Schumm‐Draeger, P. (2014) · Springer eBooks · doi:10.1007/978-3-642-41358-2_3
Understanding the link between diabetes and cancer
Morris, D. (2026) · Independent Nurse · doi:10.12968/indn.2026.3.14
Metadata
- Authors
- Rosenstock, J., Fonseca, V., McGill, J. B., Riddle, M., Hallé, J. P., Hramiak, I., Johnston, P., & Davis, M.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Tulane University (US)
- Washington University in St. Louis (US)
- Oregon Health & Science University (US)
- Université de Montréal (CA)
- Western University (CA)
- University of Wisconsin–Madison (US)
- Corresponding author
- Rosenstock, J.
- Venue
- Diabetologia
- Published
- 2009-07-16
- Volume
- 52
- Issue
- 9
- Pages
- 1971-1973
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- PMC
- PMC2723677
- OpenAlex
- W2135096382
- Cited by
- 141
- References
- 5
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 1 · 2022: 1 · 2021: 1 · 2020: 1 · 2019: 3 · 2018: 3 · 2017: 1 · 2016: 5 · 2015: 6 · 2014: 14 · 2013: 16 · 2012: 16
- FWCI
- 20.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Diabetologia (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- GlaxoSmithKline
- Sanofi
- Tulane University
- McGill University
- MannKind Corporation
- Daiichi-Sankyo
- Novo Nordisk
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- insulin glargine, neutral protamine Hagedorn insulin, type 2 diabetes, cancer risk, cancer incidence, long-acting insulin, insulin analogues
- MeSH terms
- Insulin Glargine, Diabetes Mellitus, Type 2, Diabetic Retinopathy, Humans, Hypoglycemic Agents, Insulin, Insulin, Isophane, Neoplasms, Risk Factors, Insulin, Long-Acting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
